Genomic landscape of salivary gland tumors

Oncotarget

Volumn 6, Issue 28, 2015, Pages 25631-25645

  Kato, Shumei ^a   Elkin, Sheryl K ^b   Schwaederle, Maria ^c   Tomson, Brett N ^b   Helsten, Teresa ^c   Carter, Jennifer L ^b   Kurzrock, Razelle ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b N of One   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Genomic landscape; Next generation sequencing; Personalized therapy; Salivary gland tumor; Targeted therapy

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYCLINE; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MDM2; PROTEIN P53; ANTINEOPLASTIC AGENT; TUMOR MARKER;

AKT1 GENE; AKT3 GENE; ARTICLE; CANCER SURVIVAL; CCND1 GENE; CDK4 GENE; CDK6 GENE; CDKN2A GENE; CDKN2B GENE; CONTROLLED STUDY; DRUG APPROVAL; GENE; GENE DISRUPTION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CORRELATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MDM2 GENE; NEXT GENERATION SEQUENCING; NOTCH1 GENE; NOTCH2 GENE; ONCOGENE H RAS; OVERALL SURVIVAL; PIK3CA GENE; PIK3R1 GENE; PREVALENCE; PROTO ONCOGENE; PTEN GENE; RETROSPECTIVE STUDY; SALIVARY GLAND CANCER; STRUCTURAL GENOMICS; TP53 GENE; DNA MICROARRAY; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME; MULTIVARIATE ANALYSIS; MUTATION; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; RISK FACTOR; SALIVARY GLAND NEOPLASMS; SIGNAL TRANSDUCTION; STATISTICAL MODEL;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PATIENT SELECTION; PHENOTYPE; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; SALIVARY GLAND NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84944474508     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4554     Document Type: Article

References (51)

1. Barnes L, World Health Organization and International Agency for Research on Cancer. (2005). Pathology and genetics of head and neck tumours: World Health Organization.
2. Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M and Licitra L. Major and minor salivary gland tumors. Crit Rev Oncol Hematol. 2010; 74:134-148.
3. Wahlberg P, Anderson H, Biorklund A, Moller T and Perfekt R. Carcinoma of the parotid and submandibular glands--a study of survival in 2465 patients. Oral Oncol. 2002; 38:706-713.
4. Al-Khiro FI. Salivary gland tumors: A review of 171 cases, with particular reference to histological types, site, age and gender distribution. Journal of Baghdad College of Dentistry. 2014; 26:88-91.
5. Jones AV, Craig GT, Speight PM and Franklin CD. The range and demographics of salivary gland tumours diagnosed in a UK population. Oral Oncol. 2008; 44:407-417.
6. Laurie SA and Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol. 2006; 24:2673-2678.
7. Licitra L, Marchini S, Spinazze S, Rossi A, Rocca A, Grandi C and Molinari R. Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer. 1991; 68:1874-1877.
8. Gilbert J, Li Y, Pinto HA, Jennings T, Kies MS, Silverman P and Forastiere AA. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck. 2006; 28:197-204.
9. Airoldi M, Garzaro M, Pedani F, Ostellino O, Succo G, Riva G, Sensini M, Naqe N, Bellini E, Raimondo L and Pecorari G. Cisplatin+Vinorelbine Treatment of Recurrent or Metastatic Salivary Gland Malignancies (RMSGM): A Final Report on 60 Cases. Am J Clin Oncol. 2014.
10. Licitra L, Cavina R, Grandi C, Palma SD, Guzzo M, Demicheli R and Molinari R. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol. 1996; 7:640-642.
11. Holst VA, Marshall CE, Moskaluk CA and Frierson HF, Jr. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol. 1999; 12:956-960.
12. Vered M, Braunstein E and Buchner A. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck. 2002; 24:632-636.
13. Glisson B, Colevas AD, Haddad R, Krane J, El-Naggar A, Kies M, Costello R, Summey C, Arquette M, Langer C, Amrein PC and Posner M. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res. 2004; 10:944-946.
14. Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N and Loning T. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer. 2005; 103:2526-2533.
15. Nasser SM, Faquin WC and Dayal Y. Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am J Clin Pathol. 2003; 119:801-806.
16. Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, Li Y, et al. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clin Cancer Res. 2013; 19:480-490.
17. Fan CY, Melhem MF, Hosal AS, Grandis JR and Barnes EL. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg. 2001; 127:1075-1079.
18. Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A and Levitt M. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol. 2007; 43:33-36.
19. Jakob JA, Kies MS, Glisson BS, Kupferman ME, Liu DD, Lee JJ, El-Naggar AK, Gonzalez-Angulo AM and Blumenschein GR. A Phase II study of Gefitinib in Patients with Advanced Salivary Gland Cancers. Head Neck. 2014.
20. Locati LD, Bossi P, Perrone F, Potepan P, Crippa F, Mariani L, Casieri P, Orsenigo M, Losa M, Bergamini C, Liberatoscioli C, Quattrone P, Calderone RG, Rinaldi G, Pilotti S and Licitra L. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol. 2009; 45:574-578.
21. Haddad R, Colevas AD, Krane JF, Cooper D, Glisson B, Amrein PC, Weeks L, Costello R and Posner M. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003; 39(7):724-727.
22. Agulnik M, Cohen EW, Cohen RB, Chen EX, Vokes EE, Hotte SJ, Winquist E, Laurie S, Hayes DN, Dancey JE, Brown S, Pond GR, Lorimer I, Daneshmand M, Ho J, Tsao MS, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol. 2007; 25:3978-3984.
23. Falchook GS, Lippman SM, Bastida CC and Kurzrock R. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment. Head Neck. 2014; 36:E25-27.
24. Piha-Paul SA, Cohen PR and Kurzrock R. Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol. 2011; 29:e727-730.
25. Augello C, Gregorio V, Bazan V, Cammareri P, Agnese V, Cascio S, Corsale S, Calo V, Gullo A, Passantino R, Gargano G, Bruno L, Rinaldi G, Morello V, Gerbino A, Tomasino RM, et al. TP53 and p16INK4A, but not H-KIRas, are involved in tumorigenesis and progression of pleomorphic adenomas. J Cell Physiol. 2006; 207:654-659.
26. Kishi M, Nakamura M, Nishimine M, Ikuta M, Kirita T and Konishi N. Genetic and epigenetic alteration profiles for multiple genes in salivary gland carcinomas. Oral Oncol. 2005; 41:161-169.
27. Kiyoshima T, Shima K, Kobayashi I, Matsuo K, Okamura K, Komatsu S, Rasul AM and Sakai H. Expression of p53 tumor suppressor gene in adenoid cystic and mucoepidermoid carcinomas of the salivary glands. Oral Oncol. 2001; 37:315-322.
28. Papadaki H, Finkelstein SD, Kounelis S, Bakker A, Swalsky PA and Kapadia SB. The role of p53 mutation and protein expression in primary and recurrent adenoid cystic carcinoma. Hum Pathol. 1996; 27:567-572.
29. Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, Naing A, Falchook GS, Fu S, Piha-Paul S, Tsimberidou AM and Kurzrock R. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression- free survival and bevacizumab-containing therapy. Oncotarget. 2013; 4:705-714.
30. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gomez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horvath Z, Coccia-Portugal M, Domont J, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012; 379:633-640.
31. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674. 32. Malumbres M and Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009; 9:153-166.
32. Malumbres M and Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009; 9:153-166.
33. Rocca A, Farolfi A, Bravaccini S, Schirone A and Amadori D. Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer. Expert Opin Pharmacother. 2014; 15:407-420.
34. Kato S, Schwaederle M, Daniels GA, Piccioni D, Kesari S, Bazhenova L, Shima K, Parker BA, Fanta P and Kurzrock R. Cyclin-Dependent Kinase Pathway Aberrations in Diverse Malignancies: Clinical and Molecular Characteristics. Cell Cycle. 2015; 14:1252-1259.
35. Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA and Kurzrock R. Cyclin alterations in diverse cancers: Outcome and co-amplification network. Oncotarget. Oncotarget. 2015; 6:3033-3042.
36. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006; 24(11):1770-1783.
37. Sheppard KE and McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res. 2013; 19:5320-5328.
38. Etges A, Nunes FD, Ribeiro KC and Araujo VC. Immunohistochemical expression of retinoblastoma pathway proteins in normal salivary glands and in salivary gland tumours. Oral Oncol. 2004; 40:326-331.
39. Moller MB, Ino Y, Gerdes AM, Skjodt K, Louis DN and Pedersen NT. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. Leukemia. 1999; 13:453-459.
40. Polager S and Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer. 2009; 9:738-748.
41. Khoo KH, Verma CS and Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014; 13:217-236.
42. Yang HW, Shin MG, Lee S, Kim JR, Park WS, Cho KH, Meyer T and Heo WD. Cooperative activation of PI3K by Ras and Rho family small GTPases. Mol Cell. 2012; 47:281-290.
43. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I and Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One. 2011; 6:e22769.
44. Loi S, Michiels S, Baselga J, Bartlett JM, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Dixon JM, Piccart MJ and Sotiriou C. PIK3CA genotype and a PIK3CA mutationrelated gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. PLoS One. 2013; 8:e53292.
45. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ and Kurzrock R. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014; 6:377-387.
46. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012; 13:773-781.
47. Stephens PJ, Davies HR, Mitani Y, Van Loo P, Shlien A, Tarpey PS, Papaemmanuil E, Cheverton A, Bignell GR, Butler AP, Gamble J, Gamble S, Hardy C, Hinton J, Jia M, Jayakumar A, et al. Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest. 2013; 123:2965-2968.
48. Vidwans SJ, Turski ML, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J and Kurzrock R. A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience. 2014; 1:614 -623.
49. Kurzrock R and Giles FJ. Precision Oncology for Patients with Advanced Cancer: The Challenges of Malignant Snowflakes. Cell Cycle. 2015; 14:2219-21.
50. Wheler JJ, Lee JJ and Kurzrock R. Unique Molecular Landscapes in Cancer: Implications for Individualized, Curated Drug Combinations. Cancer Res. 2014; 74:7181-4.
51. Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, et al. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget. 2014; 5:2349-2354.